Article
A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
Blood - 20 Sept 2012
Meeks Shannon L, Cox Courtney L, Healey John F, Parker Ernest T, Doshi Bhavya S, Gangadharan Bagirath, Barrow Rachel T, Lollar Pete
Abstract excerpt
A main complication of treatment of patients with hemophilia A is the development of anti-factor VIII (fVIII) antibodies. The immunogenicity of fVIII potentially is a function of its procoagulant activity, which may result in danger signals that drive the immune response. Alternatively, intrinsic structural elements in fVIII may be particularly immunogenic. Finally, VWF, the carrier protein for fVIII in plasma,...
Topics
- Animals
- Antibody Formation
- Blood Coagulation
- Enzyme-Linked Immunosorbent Assay
- Factor VIII
- Factor Xa
- Hemophilia A
- Mice
- Mice, Knockout
- Models, Animal
- Mutant Proteins
- Mutation
- Platelet Activation